A6 Pharmaceuticals is developing small molecule ARF6 inhibitors for a variety of conditions. Because ARF6 plays a critical role in pathogenic protein trafficking, inhibition of ARF6, using our proprietary compounds, has been shown to be effective in animal models of acute lung injury/acute respiratory distress, certain types of cancer, diabetic retinopathy, age-related macular degeneration, and severe cerebral malaria.
For several years, Navigen has been developing small molecule inhibitors of ARF6. In October 2017, it created a wholly owned subsidiary, A6 Pharmaceuticals, to focus on advancing the ARF6 inhibitor programs. For more information, please visit www.A6pharma.com.